Tag: Recurrent NPC therapy

Home / Recurrent NPC therapy

Categories

Toripalimab-tpzi is approved by the FDA for nasopharyngeal carcinoma

In October 2023, the FDA approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine as the first-line treatment for people with locally advanced nasopharyngeal canc...
recurrent-npc-therapy

Scan the code